GLP-1 Drugs List: Understanding the Class as a Whole

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where metabolic science, GLP-1 pathway biology, and the genetics that shape each person’s response are unpacked in plain language. Browse the full Peptides & GLP-1 library.

A search for a "GLP-1 drugs list" is really a request to understand a category — what unites the compounds people keep hearing about, how they act, and what the evidence and safety picture looks like across the group. Rather than a bare roster, this piece frames the class as a whole and the genetics that sit beneath any entry on it.

What ties the list together

Every compound people mean by "GLP-1" belongs to a GLP-1 pathway family in the receptor agonist class. For the underlying biology in plain terms, the PlexusDx primer What is GLP-1? is the place to start before comparing individual products.

The action they share

GLP-1 receptor agonists and GIP/GLP-1 dual agonists act on appetite regulation, satiety signaling, and gastric emptying, lowering caloric intake through physiology rather than willpower. Any body-weight change depends on the specific compound, dose, adherence, and individual factors, and FDA-approved weight-management dosing titrates upward from a starting dose over several weeks per each label.

The evidence behind the names

The clinical record spans SURMOUNT and SURPASS for tirzepatide, STEP and SUSTAIN for semaglutide, AWARD for dulaglutide, and LEAD and LEADER for liraglutide. Effect sizes on body weight, A1C, and cardiovascular endpoints differ by population, dose, and primary endpoint, with primary publications in The New England Journal of Medicine, The Lancet, and The Lancet Diabetes & Endocrinology. A provider can translate the outcomes that matter for you.

Shared cautions across the class

These compounds carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies and are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are most pronounced during escalation, and rare serious events include pancreatitis, gallbladder disease, and dehydration-related kidney injury.

How to read a class list without getting lost

A roster of GLP-1 compounds can feel like an undifferentiated wall of names, so a couple of organizing principles help. The most useful split is by receptor targets: single-target GLP-1 receptor agonists on one side, and GIP/GLP-1 dual agonists on the other. A second organizing axis is the approved use, since some entries are cleared primarily for type 2 diabetes and others for chronic weight management, even when the molecule overlaps across brands.

The trap to avoid is treating every name as interchangeable. The same molecule can appear under different brand names tied to different indications, and insurers frequently follow the exact brand-and-indication pairing rather than the underlying compound. That means a list is best read as a map of a category, not a menu of equivalent choices. Pairing each name with its own FDA label and the trial program it was studied in turns a bewildering list into something a person can actually reason about with a clinician.

A useful habit is to attach two facts to every name you encounter: its approved indication and the trial program behind it. That small discipline keeps a list from collapsing into interchangeable brand names and anchors each entry to real evidence.

The genetics under every entry

Whichever name on the list a conversation lands on, it acts on inherited biology. FTO shapes appetite and adiposity set-point, GLP1R is the receptor gene the drugs target, MC4R anchors satiety, and TCF7L2 connects to glucose homeostasis and GLP-1 secretion. The PlexusDx Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights — 503A-era, pathway-level education that never predicts response. Semaglutide and tirzepatide are offered through the PlexusDx Weight Management Protocols, with the genetic report as the test before you invest starting point.

Frequently Asked Questions

What unites the drugs on a GLP-1 list?

They all act on the GLP-1 pathway in the receptor agonist class, engaging appetite, satiety, and gastric emptying. Some are dual GIP/GLP-1 agonists. Each product's approved uses live in its FDA label, so a list groups compounds by mechanism rather than by identical indications or interchangeability.

Do all GLP-1 drugs work the same way?

They share a core action on appetite, satiety, and gastric emptying, but details differ. Dual GIP/GLP-1 agonists add a second incretin mechanism, and effect sizes on weight and A1C vary by compound, dose, and population. Discuss which mechanism fits your situation with a provider.

What safety concerns apply across the class?

All carry a boxed warning for thyroid C-cell tumor risk seen in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Gastrointestinal effects are common; rare serious events include pancreatitis, gallbladder disease, and dehydration-related kidney injury.

Does the genetic test rank the drugs for me?

No. The Precision Peptide Genetic Test does not predict response to any compound on a GLP-1 list. It reads pathway-level variants such as FTO and MC4R, and TCF7L2 that describe baseline metabolic biology — context for a broader conversation with your healthcare provider.

Keep exploring the PlexusDx Education Hub for more grounded, provider-minded answers. Return to the Peptides & GLP-1 library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.